How many drugs treat Non-Hodgkin's lymphoma?

Drug Landscape tracks 10 marketed treatments for Non-Hodgkin's lymphoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/non-hodgkin-s-lymphoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Non-Hodgkin's lymphoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-Hodgkin's lymphoma (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Non-Hodgkin's lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Mabthera	Rituximab-Pvvr	Roche	Monoclonal antibody	CD20 antigen on pre-B and mature B-lymphocytes	1997-01-01
Mabthera	rituximab	Roche	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	1997-01-01
Mabthera	rituxan	Roche	CD20-directed Cytolytic Antibody	B-lymphocyte antigen CD20	1997-01-01
Gliadel	CARMUSTINE	Avet Lifesciences	Alkylating Drug	Glutathione reductase, mitochondrial	1977-01-01
Liposomal Doxorubicin	liposomal-doxorubicin	Pfizer	doxorubicin	72 kDa type IV collagenase	1974-01-01
Doxorubicin Hydrochloride	doxorubicin	Pfizer	Anthracycline Topoisomerase Inhibitor	Aurora kinase A	1974-01-01
Blenoxane	BLEOMYCIN	Bristol-Myers Squibb	Cytoprotective Agent	Aspartyl/asparaginyl beta-hydroxylase	1973-01-01
Oncovin	vincristine	Pfizer Inc.	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Oncovin	Vincristine Sulfate	Pfizer Inc.	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Non-Hodgkin's lymphoma
Pfizer · 4 drugs in Non-Hodgkin's lymphoma
Roche · 3 drugs in Non-Hodgkin's lymphoma
Pfizer Inc. · 2 drugs in Non-Hodgkin's lymphoma
University of Colorado, Denver · 2 drugs in Non-Hodgkin's lymphoma
Generic (originally Schering) · 2 drugs in Non-Hodgkin's lymphoma
Generic (originally Lederle Laboratories) · 1 drug in Non-Hodgkin's lymphoma
Generic (originally Merck) · 1 drug in Non-Hodgkin's lymphoma
Generic (originally Merck/Upjohn) · 1 drug in Non-Hodgkin's lymphoma
Generic (originally Upjohn/Pfizer) · 1 drug in Non-Hodgkin's lymphoma
Hannover Medical School · 1 drug in Non-Hodgkin's lymphoma
Johann Wolfgang Goethe University Hospital · 1 drug in Non-Hodgkin's lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Non-Hodgkin's lymphoma:

Cite this brief

Drug Landscape (2026). Non-Hodgkin's lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/non-hodgkin-s-lymphoma. Accessed 2026-06-10.

Non-Hodgkin's lymphoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing